Downside risk to stock from downward revisions to FY2022 sales estimates and likely lower valuation multiples in the near-to-medium term given weaker sales growth and margin outlook.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.